Hayam G Sayyed1, Amany Osama2, Naglaa K Idriss2, Dina Sabry3, Azza S Abdelrhim4, Rania Bakry5. 1. Department of Medical Physiology, Faculty of Medicine, Assiut University Assuit, Egypt. 2. Department of Medical Biochemistry, Faculty of Medicine, Assiut University Assuit, Egypt. 3. Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Cairo University Cario, Egypt. 4. Department of Anatomy, Faculty of Medicine, Sohag University Sohag, Egypt. 5. Department of Oncological Clinical Pathology, South Egypt Cancer Institute, Assiut University Assuit, Egypt.
Abstract
BACKGROUND AND OBJECTIVE: Human umbilical cord blood (UCB) cells and bone marrow mesenchymal stem cells (BM-MSCs) have numerous advantages as grafts for cell transplantation. We hypothesized differing impacts of human UCB cells and rat BM-MSCs on reversal of hepatic injury and revival of liver function in carbon tetrachloride (CCl4)-induced liver fibrosis. METHODS: Forty rats were divided into 4 groups; control group, CCl4 group, CCl4/CD34+ group and CCl4/BM-MSCs group. Blood samples were driven from rats at 4, 8 and 12 weeks to measure serum concentration of albumin and alanine aminotransferase (ALT). Quantitative expression of collagen Iα, TGF-β, α-SMA, albumin, MMP-2, MMP-9 and TNF-α were assessed by polymerase chain reaction. Histopathological examination of the liver tissue was performed. GFP labeled cells were detected in groups injected with stem cells. RESULTS: Regarding liver function, CD34+ were more efficient than BM-MSCs in elevating albumin (P<0.05) and reducing ALT (P<0.05) concentrations. Concerning gene expression, CD34+ were more effective than BM-MSCs in reducing gene expressions of collagen Iα (P<0.01), TGF-β1 (P<0.01) and α-SMA (P<0.01). Both CD34+ and BM-MSCs have the same efficacy in reducing TNF-α (P<0.001 and P<0.01, respectively). Furthermore, CD34+ were more valuable than BM-MSCs in increasing gene expression of albumin (P<0.05) and MMP-9 (P<0.01). CONCLUSION: Taken together; human UCB CD34+ stem cells were more efficient in improvement of experimental liver injury than BM-MSCs. This study highlighted an important role of human UCB CD34+ stem cells in liver fibrosis therapy.
BACKGROUND AND OBJECTIVE:Human umbilical cord blood (UCB) cells and bone marrow mesenchymal stem cells (BM-MSCs) have numerous advantages as grafts for cell transplantation. We hypothesized differing impacts of human UCB cells and rat BM-MSCs on reversal of hepatic injury and revival of liver function in carbon tetrachloride (CCl4)-induced liver fibrosis. METHODS: Forty rats were divided into 4 groups; control group, CCl4 group, CCl4/CD34+ group and CCl4/BM-MSCs group. Blood samples were driven from rats at 4, 8 and 12 weeks to measure serum concentration of albumin and alanine aminotransferase (ALT). Quantitative expression of collagen Iα, TGF-β, α-SMA, albumin, MMP-2, MMP-9 and TNF-α were assessed by polymerase chain reaction. Histopathological examination of the liver tissue was performed. GFP labeled cells were detected in groups injected with stem cells. RESULTS: Regarding liver function, CD34+ were more efficient than BM-MSCs in elevating albumin (P<0.05) and reducing ALT (P<0.05) concentrations. Concerning gene expression, CD34+ were more effective than BM-MSCs in reducing gene expressions of collagen Iα (P<0.01), TGF-β1 (P<0.01) and α-SMA (P<0.01). Both CD34+ and BM-MSCs have the same efficacy in reducing TNF-α (P<0.001 and P<0.01, respectively). Furthermore, CD34+ were more valuable than BM-MSCs in increasing gene expression of albumin (P<0.05) and MMP-9 (P<0.01). CONCLUSION: Taken together; human UCB CD34+ stem cells were more efficient in improvement of experimental liver injury than BM-MSCs. This study highlighted an important role of human UCB CD34+ stem cells in liver fibrosis therapy.
Authors: M T Abdel Aziz; Mf El Asmar; S Mostafa; H Salama; H M Atta; S Mahfouz; N K Roshdy; L A Rashed; D Sabry; N Hasan; M Mahmoud; D Elderwy Journal: Int J Stem Cells Date: 2010-05 Impact factor: 2.500
Authors: Inge Mannaerts; Ben Schroyen; Stefaan Verhulst; Leentje Van Lommel; Frans Schuit; Marc Nyssen; Leo A van Grunsven Journal: PLoS One Date: 2013-12-17 Impact factor: 3.240
Authors: Mohammed R Khalil; Reda S El-Demerdash; Hazem H Elminshawy; Eman T Mehanna; Noha M Mesbah; Dina M Abo-Elmatty Journal: Biomed J Date: 2020-05-07 Impact factor: 4.910